ARTICLE SUMMARY:
As robotics increasingly infiltrate the operating room, Zimmer Biomet officials believe the equipment itself will become “table stakes,” widely available from multiple vendors. What will differentiate a company’s offering is a broader platform that integrates robotics with data and an ecosystem of proprietary products. A conversation with ZB Group President Ivan Tornos.
Once the epitome of high-tech medical technology, robotic systems have, in less than a decade, made tremendous leaps forward, at least in theory, in establishing their role in the future of surgery. Indeed, as Ivan Tornos, Zimmer Biomet (ZB) Group President, argues, robotically-assisted surgery now occupies so central a place that, for medtech companies, it has become “table stake,” a given in any offering.
